Sustained Disease Control
Although significant advances in the management of retinal vascular diseases have been made, there is a clear need for new therapies that can help redefine treatment expectations and address the need for better control of disease activity
Challenges in clinical practice require advances in therapies for retinal vascular diseases
Predictable lasting control of disease activity could overcome these challenges and improve outcomes for your patients
- 88% of clinicians agree patients with nAMD feel burdened by injections and less frequent injections could improve clinic capacity
- ~43% of patients on continued anti-VEGF treatment are observed to have new or changed fluid or haemorrhages following their last visit
- 79% of clinicians agree that their patients with nAMD aren’t sure if their treatment is working
Sustained Disease Control offers a clear path forward
Sustained Disease Control is the ability to achieve greater and longer lasting control of disease activity compared to current treatments and:
Via a treatment strategy that does not compromise on vision
For patients with retinal disease
Could increasing the molar dose of an anti-VEGF molecule help unlock Sustained Disease Control for your patients?
Learn the rationale behind testing a higher molar dose
We’re at a turning point for retinal vascular diseases
Bayer believes that Sustained Disease Control will set a new benchmark for the management of retinal vascular diseases, allowing patients to extend their treatment intervals while maintaining functional and anatomical outcomes and safety.
Bayer is investigating aflibercept 8mg in three pivotal studies, PHOTON, PULSAR and QUASAR.
If you want to learn more about Sustained Disease Control, please contact your local MSL.